4 Mar 2025 • A groundbreaking new treatment, Efanesoctocog alfa, is set to transform care for severe haemophilia A, a once-weekly factor VIII therapy, offering a significant improvement over current treatments requiring multiple weekly doses.

By providing effective bleeding control with a more convenient dosing regimen, this treatment has the potential to enhance quality of life and reduce treatment burden.

Experts, including the Department of Health, hail the decision as a step forward in innovative care, reinforcing the commitment to cutting-edge, cost-effective therapies for rare diseases.

Source: National Institute for Health Care and Excellence | Read Full Story